9 results
DEFM14A
LABP
Landos Biopharma Inc
25 Apr 24
Proxy related to merger
5:07pm
a Material Adverse Effect, to the knowledge of the Company, since January 1, 2021, there has not been any incident of unauthorized access or other … and the Company Subsidiaries have in place commercially reasonable security controls, an incident response plan, and disaster recovery procedures for material
PREM14A
LABP
Landos Biopharma Inc
15 Apr 24
Preliminary proxy related to merger
5:18pm
incident of unauthorized access or other unauthorized intrusion into the Company IT Assets. The Company IT Assets operate and perform in all material … ” or other malicious software. The Company and the Company Subsidiaries have in place commercially reasonable security controls, an incident response plan
DEFA14A
LABP
Landos Biopharma Inc
25 Mar 24
Additional proxy soliciting materials
9:19am
any incident of unauthorized access or other unauthorized intrusion into the Company IT Assets. The Company IT Assets operate and perform in all … ” or other malicious software. The Company and the Company Subsidiaries have in place commercially reasonable security controls, an incident response plan
8-K
EX-2.1
LABP
Landos Biopharma Inc
25 Mar 24
AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases
8:54am
or in the aggregate, have a Material Adverse Effect, to the knowledge of the Company, since January 1, 2021, there has not been any incident of unauthorized access … . The Company and the Company Subsidiaries have in place commercially reasonable security controls, an incident response plan, and disaster recovery procedures
S-1/A
EX-1.1
k62etz5ul8pkaj1eq
28 Jan 21
IPO registration (amended)
9:12am
S-1/A
EX-3.4
wg0hjryxvmk1g
28 Jan 21
IPO registration (amended)
9:12am
S-1
EX-3.2
sbbkvzo8eaeym3c
13 Jan 21
IPO registration
5:07pm
DRS/A
EX-3.2
8io8ei91
1 Dec 20
Draft registration statement (amended)
12:00am
- Prev
- 1
- Next